Status:
COMPLETED
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Niemann-Pick Disease, Type C
Eligibility:
All Genders
Up to 6 years
Phase:
PHASE1
PHASE2
Brief Summary
Niemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence. NPC results from mutatio...
Detailed Description
In the first phase of the study, infants will be treated for a total of 6 weeks, treated twice weekly. Infants will be admitted to the Neonatal Intensive Care Unit (NICU) for the first week of treatme...
Eligibility Criteria
Inclusion
- Age 0 to 6 months of age at time of enrollment, both genders, and any race/ethnicity.
- Diagnosis of NPC (either NPC1 or NPC2) based upon meeting any of the two following conditions:
- A. Two variants classified as pathogenic or likely pathogenic in NPC1/NPC2 on clinical laboratory testing, or B. One variant classified as pathogenic or likely pathogenic on clinical laboratory testing and a positive NPC biochemical marker (oxysterol or bile acid biomarker or PPCS/Lyso509) test, if acid sphingomyelinase deficiency and cholesterol ester storage disease have been excluded either by clinical molecular testing of the SMPD1 and LIPA genes or by clinical biochemical assay for acid sphingomyelinase and lysosomal acid lipase enzymes (or a combination of enzymatic and molecular testing).
- Variants will be interpreted using the American College of Medical Genetics guidelines for the interpretation of sequence variants (2015) and testing must be performed by a CLIA-certified laboratory.
- Subjects with evidence of NPC-related liver disease as defined by direct bilirubin (DB) \>2mg/dL or DB/total bilirubin ratio \>0.2.
- Ability to travel to a research site.
- Willing to participate in all aspects of trial design including serial blood collections.
- Parent / guardian must provide written informed consent to participate in the study. Because of the age range intended for inclusion, assent will not possible.
Exclusion
- Age \> 6 months at time of enrollment in the trial.
- A medical condition (such as clinically significant bleeding diathesis or evidence of immune suppression) that in the opinion of the investigator precludes placement of an intravenous catheter
- An absolute neutrophil count (ANC) of less than 1,500 per microliter.
- A platelet count less than 75,000 per microliter.
- History of severe neonatal encephalopathy, per modified Sarnat including level of consciousness as stupor/coma, absent spontaneous activity, decerebrate posture, flaccid tone, absent suck, absent moro, diverted/nonreactive pupils, lack of heart rate variability, apnea.
- Subjects, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation. Examples of inability to comply include unwillingness to relocate or travel to a study site, suspected noncompliance with study procedures, behavior that jeopardizes the safety or security of the data or study staff, and other causes of inability to comply.
- Concurrent participation in another investigational drug trial.
- History of renal disease or evidence of acute kidney injury defined as serum creatinine greater than 1.5 mg/dL or an increase of at least 0.2-0.3 mg/dL per day.
Key Trial Info
Start Date :
February 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 4 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03471143
Start Date
February 22 2019
End Date
October 4 2024
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Louis Children's Hospital
St Louis, Missouri, United States, 63110